

BURUNDI

Number of new cases

7 997

Number of deaths


5 760

Number of prevalent cases (5-year)

13 833


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	6 268 146	6 356 699	12 624 845
Incidence*			
Number of new cancer cases	3 370	4 627	7 997
Age-standardized incidence rate	123.5	134.6	128.2
Risk of developing cancer before the age of 75 years (cum. risk %)	13.1	13.8	13.4
Top 3 leading cancers (ranked by cases)**	Prostate Kaposi sarcoma Oesophagus	Cervix uteri Breast NHL	Cervix uteri Breast Prostate
Mortality*			
Number of cancer deaths	2 431	3 329	5 760
Age-standardized mortality rate	95.3	103.4	98.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	10.1	11.0	10.6
Top 3 leading cancers (ranked by deaths)**	Prostate Oesophagus Liver	Cervix uteri Breast Oesophagus	Cervix uteri Breast Prostate
Prevalence*			
5-year prevalent cases	5 499	8 334	13 833



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	822	24.4%
2nd	Kaposi sarcoma	287	8.5%
3rd	Oesophagus	285	8.5%
4th	Liver	208	6.2%
5th	NHL	202	6.0%
-	Others	1 566	46.5%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	1 457	31.5%
2nd	Breast	863	18.7%
3rd	NHL	176	3.8%
4th	Colorectum	175	3.8%
5th	Oesophagus	173	3.7%
-	Others	1 783	38.5%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	1 457	18.2%
2nd	Breast	863	10.8%
3rd	Prostate	822	10.3%
4th	Oesophagus	458	5.7%
5th	Kaposi sarcoma	446	5.6%
-	Others	3 951	49.4%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Cervix uteri	1 457	1	18.2	4.7	1 081	1	18.8	4.0	2 667	42.0
Breast	863	2	10.8	2.8	513	2	8.9	1.7	1 597	25.1
Prostate	822	3	10.3	4.5	475	3	8.2	2.6	1 207	19.3
Oesophagus	458	4	5.7	1.0	440	4	7.6	1.0	717	5.7
Kaposi sarcoma	446	5	5.6	0.45	270	7	4.7	0.28	736	5.8
NHL	378	6	4.7	0.45	265	8	4.6	0.36	757	6.0
Colorectum	359	7	4.5	0.74	274	6	4.8	0.59	610	4.8
Liver	347	8	4.3	0.68	325	5	5.6	0.66	540	4.3
Stomach	284	9	3.6	0.65	256	9	4.4	0.59	457	3.6
Leukaemia	194	10	2.4	0.22	155	11	2.7	0.20	367	2.9
Lung	182	11	2.3	0.40	167	10	2.9	0.37	283	2.2
Ovary	165	12	2.1	0.54	125	12	2.2	0.48	290	4.6
Kidney	128	13	1.6	0.10	91	13	1.6	0.09	261	2.1
Bladder	108	14	1.4	0.24	66	17	1.1	0.15	194	1.5
Lip, oral cavity	101	15	1.3	0.20	74	16	1.3	0.16	175	1.4
Brain CNS	99	16	1.2	0.13	86	14	1.5	0.13	214	1.7
Pancreas	81	17	1.0	0.18	81	15	1.4	0.18	104	0.82
Hodgkin lymphoma	80	18	1.0	0.08	43	20	0.75	0.06	170	1.4
Thyroid	77	19	0.96	0.14	30	23	0.52	0.07	142	1.1
Nasopharynx	72	20	0.90	0.11	48	18	0.83	0.09	138	1.1
Corpus uteri	71	21	0.89	0.29	22	26	0.38	0.10	148	2.3
Penis	64	22	0.80	0.29	32	22	0.56	0.16	119	1.9
Larynx	62	23	0.78	0.13	46	19	0.80	0.10	108	0.86
Melanoma	51	24	0.64	0.11	24	25	0.42	0.05	97	0.77
Vulva	49	25	0.61	0.13	30	23	0.52	0.10	98	1.5
Multiple myeloma	45	26	0.56	0.10	38	21	0.66	0.09	77	0.61
Salivary glands	26	27	0.33	0.05	20	27	0.35	0.04	51	0.40
Oropharynx	25	28	0.31	0.06	15	28	0.26	0.04	41	0.32
Hypopharynx	15	29	0.19	0.04	10	29	0.17	0.02	15	0.12
Testis	15	29	0.19	0.06	6	32	0.10	0.04	30	0.48
Vagina	14	31	0.18	0.04	10	29	0.17	0.03	23	0.36
Gallbladder	9	32	0.11	0.02	7	31	0.12	0.02	15	0.12
All cancers	7 997	-	-	13.4	5 760	-	-	10.6	13 833	-
All cancers excl. NMSC	7 873	-	-	13.2	5 707	-	-	10.5	13 582	-

Data source and methods

Incidence



Country-specific data source: No data
Method: No data: the rates are those of neighbouring countries or registries in the same area

Mortality

Country-specific data source: No data
Method: Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

